Biomatics Capital Partners, L.P. - Jun 16, 2021 Form 3 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
10%+ Owner
Signature
/s/ Julie Sunderland, Managing Member of Biomatics Capital Management, L.L.C., the general partner of Biomatics Capital Partners, LP.
Stock symbol
VERV
Transactions as of
Jun 16, 2021
Transactions value $
$0
Form type
3
Date filed
6/16/2021, 08:07 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VERV Series A Preferred Stock Jun 16, 2021 Common Stock 1.54M Direct F1, F2
holding VERV Series A-2 Preferred Stock Jun 16, 2021 Common Stock 974K Direct F1, F2
holding VERV Series B Preferred Stock Jun 16, 2021 Common Stock 88.7K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of the Issuer's preferred stock is convertible into common stock on an approximately 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
F2 These shares are held by Biomatics Capital Partners, LP ("Biomatics LP"). Biomatics Capital Management, L.L.C. ("Biomatics GP") is the general partner of Biomatics LP. Julie Sunderland and Boris Nikolic ( the "Managing Members") are the managing members of Biomatics GP. Each of the Managing Members may be deemed to share voting and dispositive power over these shares. Each of the Managing Members and Biomatics GP disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.